SANIOS Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.12 |
| 52 Week High | kr0 |
| 52 Week Low | kr0 |
| Beta | 1 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -90.63% |
| 5 Year Change | n/a |
| Change since IPO | -92.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANIOS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.0% |
| 1Y | n/a | -19.3% | 6.7% |
Return vs Industry: Insufficient data to determine how SANIOS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SANIOS performed against the UK Market.
Price Volatility
| SANIOS volatility | |
|---|---|
| SANIOS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SANIOS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SANIOS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity.
Saniona AB (publ) Fundamentals Summary
| SANIOS fundamental statistics | |
|---|---|
| Market cap | kr206.68m |
| Earnings (TTM) | -kr95.81m |
| Revenue (TTM) | kr16.84m |
12.3x
P/S Ratio-2.2x
P/E RatioIs SANIOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANIOS income statement (TTM) | |
|---|---|
| Revenue | kr16.84m |
| Cost of Revenue | kr5.06m |
| Gross Profit | kr11.78m |
| Other Expenses | kr107.59m |
| Earnings | -kr95.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 69.96% |
| Net Profit Margin | -568.94% |
| Debt/Equity Ratio | -297.3% |
How did SANIOS perform over the long term?
See historical performance and comparison